Article

Longitudinal MRI Evaluation of Intracranial Development and Vascular Characteristics of Breast Cancer Brain Metastases in a Mouse Model

Department of Radiology, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America.
PLoS ONE (Impact Factor: 3.53). 04/2013; 8(4):e62238. DOI: 10.1371/journal.pone.0062238
Source: PubMed

ABSTRACT Longitudinal MRI was applied to monitor intracranial initiation and development of brain metastases and assess tumor vascular volume and permeability in a mouse model of breast cancer brain metastases. Using a 9.4T system, high resolution anatomic MRI and dynamic susceptibility contrast (DSC) perfusion MRI were acquired at different time points after an intracardiac injection of brain-tropic breast cancer MDA-MB231BR-EGFP cells. Three weeks post injection, multifocal brain metastases were first observed with hyperintensity on T2-weighted images, but isointensity on T1-weighted post contrast images, indicating that blood-tumor-barrier (BTB) at early stage of brain metastases was impermeable. Follow-up MRI revealed intracranial tumor growth and increased number of metastases that distributed throughout the whole brain. At the last scan on week 5, T1-weighted post contrast images detected BTB disruption in 160 (34%) of a total of 464 brain metastases. Enhancement in some of the metastases was only seen in partial regions of the tumor, suggesting intratumoral heterogeneity of BTB disruption. DSC MRI measurements of relative cerebral blood volume (rCBV) showed that rCBV of brain metastases was significantly lower (mean = 0.89±0.03) than that of contralateral normal brain (mean = 1.00±0.03; p<0.005). Intriguingly, longitudinal measurements revealed that rCBV of individual metastases at early stage was similar to, but became significantly lower than that of contralateral normal brain with tumor growth (p<0.05). The rCBV data were concordant with histological analysis of microvascular density (MVD). Moreover, comprehensive analysis suggested no significant correlation among tumor size, rCBV and BTB permeability. In conclusion, longitudinal MRI provides non-invasive in vivo assessments of spatial and temporal development of brain metastases and their vascular volume and permeability. The characteristic rCBV of brain metastases may have a diagnostic value.

0 Followers
 · 
52 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The most common types of malignant brain tumors in adults are brain metastasis and primary glioblastoma multiforme (GBM), both of which are highly lethal, with a median survival of less than a year. A critical challenge in treating brain tumors is the delivery of drugs to the central nervous system (CNS). The blood brain barrier (BBB), which has been shown to be partially disruptive even in the late stage of these brain tumors, prevents the access of therapeutic concentrations of systemic drugs to the tumor in brain parenchyma. Nanoparticle systems can represent optimal carriers for delivery of therapeutic agents. We will summarize various strategies used to improve nano-delivery of imaging contrast or therapeutic agents across BBB to brain tumors. Recent advances in molecular and cellular identifications of neurooncological biomarkers promise the advent of nanotechnology-based brain tumor-targeted detection and therapy. In this review, we will further discuss the current understanding of brain tumor biology and tumor type-specific genetic and epigenetic alterations, and advances in development of the novel nanoparticles for brain tumor imaging and therapy.
    Journal of Biomedical Nanotechnology 09/2015; 10(9). DOI:10.1166/jbn.2014.1896 · 7.58 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: At present, a radical shift in cancer treatment is occurring in terms of predictive, preventive and personalised medicine (PPPM). Individual patients will participate in more aspects of their health care. During the development of PPPM, many rapid, specific, and sensitive new methods for earlier detection of cancer will result in more efficient management of the patient, and hence a better quality of life. Coordination of the various activities among different healthcare professionals in primary, secondary, and tertiary care requires well-defined competencies, implementation of training and educational programs, sharing of data, and harmonized guidelines. In this position paper the current knowledge to understand cancer pre-disposition and risk factors, the cellular biology of cancer, predictive markers and treatment outcome, the improvement in technologies to screen, diagnose and provision of better drug development solutions, are discussed in the context of a better implementation of personalised medicine. Recognition of the major risk factors for cancer initiation is the key for preventive strategies [1]. Of interest, cancer predisposing syndromes in particular the monogenic subtypes that lead to cancer progression are well defined and one should focus on implementation strategies to identify individuals at risk to allow preventive measures and early screening/diagnosis. Implementation of such measures are disturbed by improper use of the data, with breach of data protection as one of the risks to be heavily controlled. Population screening requires in depth cost-benefit analysis to justify health care costs and the parameters screened should provide information that allow an actionable deliverable, for better health care provision. http://www.epmajournal.com/content/pdf/s13167-015-0030-6.pdf
    EPMA Journal, The 04/2015; 6:9. DOI:10.1186/s13167-015-0030-6
  • [Show abstract] [Hide abstract]
    ABSTRACT: Phosphatidylserine (PS), normally restricted to the inner leaflet of the plasma membrane, becomes exposed on the outer surface of viable endothelial cells in tumor vasculature, but not in normal blood vessels. In the present study, we report the use of PGN635, a novel human monoclonal antibody that specifically targets PS, for in vivo molecular MRI of tumor vasculature. The F(ab')2 fragments of PGN635 were conjugated to polyethylene glycol (PEG) coated iron oxide nanoparticles (IO). Targeting specificity of the PS-targeted Nanoprobe, IO-PGN635F(ab')2 was first confirmed by in vitro MRI and histological staining. In vivo longitudinal MRI was then performed before and after i.v. injection of IO-PGN635F(ab')2 into mice bearing 4T1 breast tumors. T2-weighted MR images at 9.4 T revealed inhomogeneous signal loss in tumor as early as 2 h post injection. Furthermore, ionizing radiation induced a significant increase in PS exposure on tumor vascular endothelial cells, resulting in significantly enhanced and sustained tumor contrast (p < 0.05). Spatially heterogeneous MRI contrast correlated well with histological staining of tumor vascular endothelium. Our studies suggest that PS exposed within the lumen of tumor vasculature is a highly specific and useful biomarker for targeted MRI contrast agents.
    Journal of Biomedical Nanotechnology 05/2014; 10(5):846-55. DOI:10.1166/jbn.2014.1851 · 7.58 Impact Factor

Full-text (3 Sources)

Download
38 Downloads
Available from
Jun 2, 2014